Business Wire

IDEMIA

Share
Brazil Tests the World's First Facial Recognition Shuttle Service

The Project Embarque + Seguro 100% Digital Boarding System, using the Brazilian government’s facial recognition, arrives this Tuesday (June 15) at the Congonhas Airport (SP). For the first time in the world, passengers on the air shuttle service between the capitals of São Paulo and Rio de Janeiro will participate in the simultaneous testing of this end-to-end technology without the need to present neither a boarding pass nor an identification document. The Project of the Ministry of Infrastructure, developed in partnership with Serpro and the Special Secretariat of Debureaucratization, Management and Digital Government of the Ministry of Economy, has already been tested at the airports of Florianópolis (SC), Salvador (BA), Santos Dumont (RJ) and Belo Horizonte (Confins).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005505/en/

After the approval of the pilot project, the Federal Government will move forward with actions to effectively implement the technology in major Brazilian airports. The technology aims at making the boarding process at airports more efficient, agile, and secure. "It is the first time that tests are carried out simultaneously in two of our airports, thus establishing, in an unprecedented way, a 100% biometric air shuttle between RJ / SP, which has the fifth-largest movement in the world", highlights the executive secretary of MInfra, Marcelo Sampaio.

Throughout the day, Azul Linhas Aéreas’s passengers travelling between Congonhas and Santos Dumont airports will be invited to try the biometric facial recognition technology to access both boarding area and aircraft at both terminals. "Embarque + Seguro combines biometric validation and data analysis, ensuring an accurate, agile and secure validation of the identity of passengers, who can thus travel with more comfort and tranquility. The solution complies with the General Data Protection Law (LGPD) and is premised on security in the processing of personal data against misuse or unauthorized use", emphasizes the president of Serpro, Gileno Barreto.

For the president of Infraero, Brigadier Paes de Barros, "the air shuttle’s Embarque + Seguro unites two essential items that streamline the boarding processes, which are safety and ease for the passenger and the entire civil aviation system".

According to the Director of Public Security & Identity (PSI) of IDEMIA in Brazil, Márcio Lambert, "Facial recognition is a global trend and the Project Embarque + Seguro, jointly carried out by Minfra and Serpro, shows that Brazil is on the right track to airport digitalization. IDEMIA’s technology is applied in the most modern airports around the world, such as Changi in Singapore, and offers a high level of security for passengers, airlines, and airport operators, as its algorithm is highly accurate, reaching a extremely high authenticity rate in the identification of individuals. IDEMIA is proud to participate in this project along with Brazil’s Federal Government and to enable the world’s first 100% end-to-end digitized boarding system in an executive air shuttle service".

"The latest Global Passengers Research conducted by the International Air Transport Association (IATA) says that 70% of interviewees are willing to share their biometry for identification purposes during the boarding process. Our global expertise contributes to meeting society’s need to fly again. This innovative project developed by the Federal Government allows travelers to enjoy a quieter, safer and more comfortable boarding experience and puts Brazil at the forefront of the digital transformation movement. IDEMIA as a global leader in augmented identity has the mission to facilitate the flow of passengers by creating the possibility to interact and travel in a more connected way. To participate in the first air shuttle with an end-to-end fully digitized boarding system, in both airports, is an important milestone in our history,” explains Rodrigo Costa, PSI business development director at IDEMIA LATAM.

The MFACE technology, developed by IDEMIA, captures facial biometrics in seconds, making the boarding process even more agile, avoiding queues and delays. The solution combines the convenience and security of data validation, respecting the privacy of passengers according to the GDPR, and ensures a more hygienic process by eliminating document and paper handling, thus avoiding the risk of contamination.

"The control of IDEMIA’s biometric system follows high-quality, reliability and safety standards and offers more agility and comfort to passengers, turning the airport operational process more intelligent, the airline passenger identification more accurate, and generates the security required by the government," adds Márcio Lambert.

How it works

When checking in at the airport, the passenger of Azul Linhas Aéreas is invited to participate in the project. If the passenger agrees, then a message is sent to the cell phone informed in the application, requesting authorization to obtain the passenger’s data, including the social security number and a photo. Upon consent, the airline attendant, using the application developed by Serpro for this purpose, performs the biometric validation of the citizen, comparing the data and the photo taken on the spot with the government databases.

After validated, the passenger is released to enter the departure hall and the aircraft passing through biometric control points, whose cameras perform the passenger’s identification without the need for the user to present any document or boarding pass.

Total Security

In the pilot project, indicators such as queue time reduction, access to the departure hall and aircraft are measured, in addition to operating costs. With the tests, it is expected that airport security increases, as facial recognition allows an accurate identification of passengers.

"We are moving towards a fully secure biometric boarding at every airport in the country. In addition to the process being safe from the sanitary point of view, by eliminating the handling of papers during the pandemic, it guarantees the total protection of users' data, because the Embarque + Seguro 100% Digital Boarding System meets all the precepts of the LGPD", says Marcelo Sampaio.

Partnerships

Serpro is MInfra’s strategic partner in the country's transportation digital agenda, but Embarque + Seguro also has the collaboration of airlines and airports where the tests have been carried out, which has enabled the improvement of the project at each stage. The air shuttle pilot test is being implemented with the support of Infraero and Azul Linhas Aéreas; and the technology of facial identification stations was developed by Digicon, IDEMIA and Azul/Pacer companies.

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated, and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release

Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye